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Abstract
Objectives: Squamous cell carcinoma is the most common cancer of the oral cavity, and several etiologic factors 
are involved in its development. Single nucleotide polymorphism (SNP) of the P53 gene codon 72 (P53c72) chang-
es the structure of the protein and affects its activity. The prevalence of P53c72 different genotypes, which seems 
to vary with race and geographic location, has shown a strong correlation with many types of human cancers. The 
aim of this study was to investigate the correlation between P53c72 polymorphism and risk of oral squamous cell 
carcinoma (OSCC) in the heavily populated Gilan Province in northern Iran.  
Design of Study: This case-control study was done on 55 paraffin-embedded samples from OSCC patients and 
100 samples of non-dysplastic oral cavity lesions. The P53c72 genotypes were determined using the ARMS-PCR 
method.  SPSS-15 software was used for statistical analysis.
Results: There were no significant statistical differences found between the prevalence of different P53c72 geno-
types in the OSCC group vs. the control.  However, the Pro/Pro genotype in OSCC samples showed a strong 
correlation with age, as 70% of such patients were below 50 years old.  Interestingly, a large portion (40%) of the 
patients with the Pro/Pro genotype had the tumor in the lip area.
Conclusions: Although P53c72 polymorphism does not appear to be a predisposing factor for OSCC in the popula-
tion of Northern Iran, the Pro/Pro genotype could be considered as a risk factor for OSCC in adults below 50 years 
old and the anatomical location of the tumor.
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Introduction
Cancer remains a major problem among human societies. 
Oral squamous cell carcinomas (OSCC) are among the 
most common cancers in both sexes worldwide (http://
www-dep.iarc.fr/). Epidemiological studies indicate that 
the cause is multi-factorial and includes nutrition, use 
of tobacco and/or alcohol, viral infections, genetic fac-
tors, and UV exposure. There is also some evidence for 
involvement of some genetic predisposing factors for 
OSCC. Such genetic changes could occur in oncogenes, 
tumor suppressors, and growth regulator genes (1).                    
The P53 protein is encoded by a key tumor suppres-
sor gene (P53) with 11 exons and 10 introns located on 
the short arm of chromosome 17. P53 regulation plays 
an important role in the control of cell cycle and DNA 
damage response. In fact, P53 mutations are a common 
genetic event in most cancers, and many such mutations 
increase cell proliferation, hamper apoptosis, and often 
lead to genetic instability (2,3).
It has been reported that in addition to mutations, ge-
netic polymorphisms could also have an influence on 
the P53 performance. In particular, there is an interest 
in P53 codon 72 (P53c72) single nucleotide polymor-
phism (SNP) that could result in either arginine (Arg) 
or proline (Pro) alleles and create 3 different genotypes: 
Arg/Arg, Arg/Pro, and Pro/ Pro (4). There have been 
reports showing possible involvement of P53c72 poly-
morphism in individuals’ susceptibility to cancers of 
mouth (5), breast (6), colorectal (7), lung (8), and blad-
der (9). In fact, the P53c72 polymorphism does seem to 
have a significant impact on the P53 protein function: 
the presence of Arg at this position, compared to Pro, 
has been shown to result in a greater ability to induce 
apoptosis in vitro. These two different alleles also dif-
fer in terms of protein structure, transcriptional activity, 
and carcinogenesis (10).
The impact of the P53c72 polymorphism appears to de-
pend on geographic distributions and race.  Although 
OSCC is common in Iran, there have been only a few 
studies, with limited scopes, conducted on it in some 
limited parts of the country (11-13). Therefore, addition-
al research could provide some useful information and 
insight on OSCC etiology among the Iranian popula-
tion. The main aim of this study was to assess the rate of 
different P53c72 genotypes in OSCC samples from the 
city of Rasht, the center of the heavily-populated Gilan 
province that is located in the north of Iran.  Many of the 
residents in this area belong to the Gilak ethnic group 
and a good number of them are farmers.  
 
Material and Methods
2.1. Samples and Selection Criteria
In this case-control study, 55 paraffin-embedded sam-
ples from patients with OSCC, as the case group, and 
100 samples from patients with non-dysplastic lesions 
of the oral cavity, as the control group, were obtained 
from the Central Laboratory of the Facial Lesions in the 
Province of Gilan. The case group consisted of all pa-
tients with OSCC registered from 2005 to 2011 in the 
area of study.  All OSCC diagnoses were reviewed and 
approved by two independent Oral and Maxillofacial 
pathologists. 
2.2. P53 Genotyping
Genomic DNA extraction was done by using QiaAmp 
DNA mini kit (QIAGEN) following the manufacturer’s 
instruction.  To remove RNA contamination, RNAse A 
was used during the extraction process.  In order to con-
trol the quality and concentration of the extracted DNA 
samples, each sample was analyzed by a nano-drop 
spectrophotometer at wavelengths of 260 and 280 nm. 
The ARMS-PCR process using specific primers was 
done with the following steps:
Each PCR was performed by using 200-250 ng of 
gDNA, 10 mM Tris-Hcl, 50 mM KCl, 2.5 mM MgCl2, 
one unit of Taq DNA polymerase enzyme, 200 mM of 
each of the nucleotides (dGTP, dTTP, dCTP, and dATP), 
and 50 pico moles of each pair of specific primers for 
amplification of either proline or arginine (Table 1). 
All reactions were done with Corbett: Rotor-gene 6000. 
Primer Sequence 
Pro-F 5'-GCC AGA GGC TGC TCC CCC-3' 
Pro-R 5'-CGT GCA AGT CAC AGA CTT-3' 
Arg-F 5'-TCC CCC TTG CCG TCC CAA-3' 
Arg-R 5'-CTG GTG CAG GGG CCA CGC-3' 
Table 1. Sequences of the primers used for ARMS-PCR.
The PCR program for amplification of the Arg SNP was 
5 minutes at 94°C, followed by 35 cycles of 45 sec at 
94°C, 45 sec at 61°C, and one min at 72°C, followed by a 
10 min cycle at a of 72°C.  For the Pro SNP amplification, 
the program ran as 5 minutes at 94°C, followed by 35 
cycles of 45 sec at a 92°C, 45 sec at 55°C, and one minute 
at 72°C, followed by a 10 min cycle at 72°C.
In order to analyze the reaction products, 20 µl of each 
reaction was mixed with 4 µl of the loading buffer, run on 
a 2% agarose gel in 0.5 X TBE buffer, stained with ethid-
ium bromide, and visualized on a UV transluminator.
2.3. Statistical Analysis
The data were analyzed using the SPSS version 15 soft-
ware and applying the Chi-Square or Fisher exact tests. 
P-value less than 0.05% was considered significant.
Results
A total of 55 OSCC cases including 29 males and 26 
females with a mean age of 65.87 ± 14.72 years (rang-
ing from 27 to 90 years) were studied.  Comparisons 
of the incidence of OSCC are shown on table 2. The 
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majority (25.45%) of the tumors were on the lips, fol-
lowed closely by tongue (21.81%), buccal mucosa (BM; 
20%), and gums (18.18%). The least affected areas were 
the palate and floor of the moth (FOM) with only 2 and 
5 incidences out of the total of 55, respectively. As the 
control group, one hundred individuals, including 50 
males and 50 females, with a mean age of 62.69 ± 12.99 
years and non-dysplastic lesions were included in the 
study. In the control group, the lesions were only due 
to the stimulation of the oral cavity including fibrous 
lesions (stimulative fibroma) and pyogenic granuloma, 
in which only the connective tissue had shown reactive 
changes with no neoplastic activity. Statistical analysis 
showed no significant differences regarding either the 
male and female proportions or the average age of the 
patients between the test and control groups. 
Analysis of the frequency of the P53c72 polymorphism 
in the test group shows that out of the total of 55 OSCC 
patients, 45.5% of them had the Arg /Pro genotype, fol-
lowed by Arg /Arg (36.4%) and Pro/Pro (18.2%). As 
shown in figure 1, in samples with the Pro/Pro geno-
type, a dedicated band of 177 bp was observed, in con-
trast to a 141-bp band for the Arg/Arg genotype. As 
expected, some samples with a heterozygote genotype 
contain both Arg and Pro bands. A detailed analysis 
of the distribution of P53c72 alleles and genotypes for 
OSCC cases vs. the controls is presented on table 3.
As it can be seen from the results, the frequency of the 
Arg72 allele is 5% higher among the OSCC patients 
compared with the controls. There is also a 6.2% higher 
Pro/Pro genotype among the OSCC samples. However, 
these values are not statistically significant. As for the 
distribution of tumor sites, the highest frequencies of 
Arg/Pro and Arg/Arg genotypes were observed in the 
tongue (32%) and lips (35%), respectively (Table 4).
Interestingly, when the patients are divided into two 
different age groups of either under 50 or equal and 
over 50 years, we notice that the Arg/Arg and Arg/Pro 
genotypes are highly prevalent among those above 50-
years-old (Table 5).  In fact, the vast majority (93.3%) of 
          Affected 
                 area 
Gender 
Tongue Palate FOM Lips Gums BM FOM + BM + Gums 
Female 9 1 3 1 4 7 1 
Male 3 1 2 13 6 4 0 
Total 12 2 5 14 10 11 1 
% 21.81 3.63 9.09 25.45 18.18 20 1.81 
Table 2. Demographic details of OSCC patients and tumor sites.
FOM, floor of the mouth; BM, buccal mucosa.
Fig. 1. Examples of P53 genotypes amplified by ARMS-PCR and run on an agarose gel.  Lanes: M, DNA ladder; 
C, negative (no-template) PCR control; 1-8, test PCR samples (genotypes: Arg/Arg, lanes 1, 3, 6, and 7; Pro/Pro, 
lane 2; Arg/Pro, lanes 4, 5, and 8).
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the OSCC patients above 50 had either the Arg/Arg (19; 
42.2%) or Arg/Pro (23; 51.5%) genotypes. As for the 
Pro/Pro genotype, however, about 70% of the patients 
had less than 50 years.
Discussion
Mutations of P53, a key tumor suppressor gene that 
plays central roles in response to DNA damage, control 
of the cell cycle, and regulation of apoptosis, have been 
linked with many humans cancers (14). Depending on 
the geographical area, the rate of different mutations 
can vary from 30 to 70 percent (15). About 90% of these 
mutations lead to the synthesis of a stable but nonfunc-
tional P53 protein accumulating in the nuclei of tumor 
cells (16).
Occurrence of a Single Nucleotide Polymorphism (SNP) 
at codon 72 in exon 4 of the P53 leads to the presence of 
either Arg or Pro alleles, which in turn could result in 
3 different genotypes: Arg/Arg, Arg/Pro, and Pro/Pro. 
Although the substitution of the Arg codon with Pro, or 
vice versa, affects the structure of the P53 protein, the 
mechanism by which this might affect P53 function re-
mains unclear.  In comparison to the Pro72 allele, Arg72 
seems to induce apoptosis by increasing P53 localiza-
tion to mitochondria (17).
The involvement/effect of P53c72 polymorphism in vari-
ous cancers has been controversial. For example, Storey 
and colleagues have shown that excessive expression of 
homozygous Arg72 P53 protein can increase suscep-
tibility of cervical cancer associated with HPV for up 
to seven fold (4). By contrast, Liu and colleagues have 
reported that the Pro72 P53 allele is associated with in-
creased risk for lung adenocarcinoma and SCC (18). In 
another study by Twu and colleagues, it has been re-
ported that the heterozygote Arg/Pro genotype is asso-
ciated with an increased risk of hypopharyngeal SCC 
Allele/ 
Genotype
OSCC
(n=55)
Controls
(n=100)
Fisher's 
Exact Test 
Odd's Ratio, 
(95% CI)
Arg 65 (59%) 128 (64.0%) 0.391 0.81 (0.50-1.31) 
Pro 45 (41%) 72 (36.0%) 0.311 1.23 (0.76-1.98) 
Arg/Arg 20 (36.4%) 40 (40.0%) 0.731 1.167 (0.59-2.30) 
Arg/Pro 25 (45.5%) 48 (48.0%) 0.867 1.10 (0.57-2.14) 
Pro/Pro 10 (18.2%) 12 (12.0%) 0.339 0.614 (0.25-1.52) 
Table 3. Distribution of the P53 codon 72 alleles and genotypes in OSCC samples and 
controls.
Site of Tumor
Genotype 
Total
N (%) Arg/Arg
N (%) 
Pro/Pro 
N (%) 
Arg/Pro
N (%) 
Tongue 4 (20) --- 8 (32) 12 (21.8) 
Palate --- --- 2 (8) 2 (3.6) 
FOM 1 (5) --- 4 (16) 5 (9.1) 
FOM + BM + Gums 1 (5) --- --- 1 (1.8) 
Lips 7 (35) 4 (40) 3 (12) 14 (25.5) 
Gums 3 (15) 3 (30) 4 (16) 10 (18.2) 
BM 4 (20) 3 (30) 4 (16) 11 (20) 
Total 20 (100) 10 (100) 25 (100) 55 (100) 
Table 4. Distribution of the involved area and correlation with P53c72 genotypes in 
OSCC patients.
FOM, floor of the mouth; BM, buccal mucosa.
Age Arg/Arg Arg/Pro Pro/Pro Total Statistics 
<50 1 (5%) 2 (8%) 7 (70%) 10 (18.2%) Chi-square test= 22.12 
P-value= 0.001?50 19 (95%) 23 (92%) 3 (30%) 45 (81.8%) 
Table 5. The frequency of the 3 different P53c72 genotypes in patients either below or equal and above 50 
years old.
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(19). While these findings have been confirmed by some 
other studies (20-23), they have also been contested by 
some investigators (24,25). 
There is limited information on the impact of P53c72 
polymorphism on OSCC. In a study carried out in Tai-
wan, Bau and colleagues reported that the Arg/Arg gen-
otype seems to increase the risk of oral carcinoma by 
2.7 fold (26). By contrast, we found no significant asso-
ciation between P53c72 polymorphism/genotypes and 
OSCC among the population of the Gilan Province in 
northern Iran. Our observation is similar to the results 
obtained in a study by Shen and colleagues on head and 
neck SCC (1), as well as Katiyar et al. on HPV-associ-
ated oral cancer in India (5). It is of course possible that 
such variations might be due to a variety of factors in-
cluding racial and geographic differences or predispos-
ing factors such as Alcohol consumption, tobacco use, 
and life style and risk of HPV viruses. 
The mean age of patients with OSCC in the present study 
was 65.87 ± 14.72 years. On average, female patients 
were about 6 years older than males. This was similar to 
the studies done by Sankarnarayanan et al. (27) and Jo-
vanovic et al. (28) in Netherlands and India, but different 
from Otho et al. in Nigeria (29), in which the mean age of 
the male OSCC patients was more than females.
Interestingly, among the samples studied here, the lip 
was the most common anatomical site of tumor involve-
ment (25.45%) following by tongue (21.81%) and buccal 
mucosa (20%). This is in line with a number of studies, 
in which either lip (24,25,26,27) or tongue (11,28,30,31) 
was reported as being the most common tumor site.
An important observation made in our study is that the 
frequency of OSCC patients under 50 years with the 
Prp/Pro genotype was 70%, which is statistically sig-
nificant (p=0.001).  Significant portions of the OSCC 
patients with the Arg/Pro and Arg/Arg genotypes had 
the lesions on their lips and tongues, which can suggest 
an increased risk of OSCC tumor site with certain geno-
types. However, one cannot draw any firm conclusions 
without investigating a larger sample size. Moreover, 
additional studies are required to investigate the role 
of various environmental and ethnic factors in order to 
determine the role of P53 codon 72 polymorphisms in 
OSCC.
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